## **ISPOR**

www.ispor.org


## SECOND PLENARY: Real World Evidence in Asia Pacific: Are We Ready? Is It Helpful for Decision Makers?





Kinwei Arnold Chan, MD, ScD, FISPE Health Data Research Center & National Taiwan University Hospital Taipei, Taiwan




















10+ years later, health insurance claims as RWD			
<ul> <li>PLoS O</li> </ul>	<ul> <li>PLoS One 2015 https://doi.org/10.1371/journal.pone.0122860</li> </ul>		
	RESEARCH ARTICLE		
	Clinical Outcomes in Low Risk Coronary		
	Artery Disease Patients Treated with		
	Different Limus-Based Drug-Eluting Stents - A		
	Nationwide Retrospective Cohort Study		
	Using Insurance Claims Database		
	Chao-Lun Lai <sup>1,2,3</sup> , Ching-Fen Wu <sup>4</sup> , Raymond Nien-Chen Kuo <sup>5,6</sup> , Yen-Yun Yang <sup>6</sup> , Ming-Fong Chen <sup>7</sup> , K. Arnold Chan <sup>8,9</sup> , Mei-Shu Lai <sup>3,6</sup> *		
<ul> <li>Head-to-head comparisons of different stents</li> </ul>			
2018.9.10	AP ISPOR		









HIRA data i	n South Korea
	RESEARCH ARTICLE
<ul> <li>PLoS One</li> </ul>	Differential Cardiovascular Outcomes after
2015; 10(5): e0124287	Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea,
	and Pioglitazone Therapy, All in Combination
	with Metformin, for Type 2 Diabetes: A
• N = 349,476	Population-Based Cohort Study
	Jong-Mi Seong <sup>1,2©</sup> , Nam-Kyong Choi <sup>3,4©</sup> , Ju-Young Shin <sup>5</sup> , Yoosoo Chang <sup>6</sup> , Ye-Jee Kim <sup>7</sup> , Joongyub Lee <sup>3</sup> , Ju-Young Kim <sup>8</sup> , Byung-Joo Park <sup>1,2,5,7</sup> *
	1 Office of Drug Safety Information II, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea, 2 Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 3 Division of Clinical Epidemiology, Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital, Seoul, Republic of Korea, 4 Medical Research Center, Seoul National University, Seoul, Republic of Korea, 5 Office of Drug Utilization Review, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea, 6 Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea, 7 Office of Drug Safety & Risk Management, Seoul, Republic of Korea, 8 Department of Family Medicine, Seoul National University Bundang Hospital, Seoul, Republic of Korea
2018.9.10	























# Historically, some unfortunate dichotomy

- Randomized trials vs. Non-randomized studies
- Primary data vs. Secondary data
- Prospective vs. Retrospective
- Pre- vs. Post-marketing
- Validity vs. generalizability
- Ideally, different types of data complement each other – fit for purpose


```
2018.9.10
```


AP ISPOR






Two health insurance claims-based studies The NEW ENGLAND JOURNAL of MEDICINE				
	OR IGINAL ARTICLE			
Funded by US FDA	2011; 365: 1896-904 ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults			
J Am Heart Assoc. 2017;6:e005362	<ul> <li>William O. Cooper, M.D., M.P.H., Laurel A. Habel, Ph.D.,</li> <li>Colin M. Sox, M.D., K. Arnold Chan, M.D., Sc.D., Patrick G. Arbogast, Ph.D.,</li> <li>T. Craig Cheetham, Pharm.D., Katherine T. Murray, M.D.,</li> <li>Virginia P. Quinn, Ph.D., M.P.H., C. Michael Stein, M.B., Ch.B.,</li> <li>S. Todd Callahan, M.D., M.P.H., Bruce H. Fireman, M.A.,</li> <li>Frank A. Fish, M.D., Howard S. Kirshner, M.D., Anne O'Duffy, M.D.,</li> <li>Frederick A. Connell, M.D., M.P.H., and Wayne A. Ray, Ph.D.</li> </ul>			
Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients				
Chao-Lun Lai, MD, PhD; Ho-Min Chen, MS; Min-Tsun Liao, MD; Ting-Tse Lin, MD; K. Arnold Chan, MD, ScD				
<ul> <li>Validation of cardiovascular outcomes was carried out in one</li> </ul>				
study, but not the other				
2018.9.10 AP ISPO	DR			
























#### **ISPOR**

www.ispor.org

## SECOND PLENARY: Real World Evidence in Asia Pacific: Are We Ready? Is It Helpful for Decision Makers?



Kinwei Arnold Chan, MD, ScD, FISPE Health Data Research Center & National Taiwan University Hospital Taipei, Taiwan

